Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19003561 | 0.87 | KCNA5 (0.33) | TSHRKCNA5KCNH2CYP2D6KCNE1 | |
| SCHEMBL12293361 | 0.85 | HDAC8 (0.31) | TSHRHDAC8 | |
| SCHEMBL26013540 | 0.82 | BDKRB2 (0.33) | ALDH1A1CYP2D6 | |
| SCHEMBL13632434 | 0.81 | KCNA5 (0.35) | TSHRKCNA5KCNH2CYP2D6KCNE1 | |
| SCHEMBL26546032 | 0.79 | NR1I2 (0.41) | KCNH2HSP90AA1 | |
| SCHEMBL2629790 | 0.76 | HSP90AA1 (0.33) | HSP90AA1 | |
| SCHEMBL14553998 | 0.76 | TSHR (0.38) | TSHRKCNA5KCNH2HDAC8ALDH1A1 | |
| SCHEMBL10202056 | 0.76 | TSHR (0.38) | TSHRKCNA5KCNH2HDAC8ALDH1A1 | |
| SCHEMBL13663803 | 0.76 | TSHR (0.38) | TSHRKCNA5KCNH2HDAC8ALDH1A1 | |
| SCHEMBL23709479 | 0.75 | BDKRB2 (0.35) | KCNA5KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339882-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| WO-2023076218-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-4092012-A1 | PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2022-11-23 | — | — | EP | disclosed |
| WO-2022197755-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2021-07-08 | — | — | US | disclosed |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2021-03-16 | — | — | US | disclosed |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ROIVANT SCIENCES GMBH (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES, GmbH (CH) | 2020-05-26 | — | — | US | disclosed |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ROIVANT SCIENCES GMBH (CH) | 2019-07-16 | — | — | US | disclosed |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | ALTAVANT SCIENCES GMBH (CH) | 2018-04-05 | — | — | US | disclosed |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20160008339-A1 | PSORALEN DERIVATIVES FOR PREVENTING OR TREATING HEART FAILURE OR CARDIAC HYPERTROPHY | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2016-01-14 | — | — | US | disclosed |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-07-28 | — | — | US | disclosed |
| US-20090270421-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-10-29 | — | — | US | disclosed |
| EP-2093220-A2 | Inhibitors of fatty acid amide hydrolase | The Scripps Research Institute (US) | 2009-08-26 | — | — | EP | disclosed |
| CN-1167788-C | Encapsulated perfume particles and detergent compsns. contg. said particles | — | 2004-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160008339-A1 | PSORALEN DERIVATIVES FOR PREVENTING OR TREATING HEART FAILURE OR CARDIAC HYPERTROPHY | PAH, P4HA1, NPR3 | TSHR 436/4885KCNA5 2338/4885KCNH2 2033/4885 |
| US-10660893-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | TSHR 1218/4885KCNA5 3294/4885KCNH2 3159/4885 |
| US-20200237760-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | TSHR 1218/4885KCNA5 3294/4885KCNH2 3159/4885 |
| US-20180092918-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | TSHR 1218/4885KCNA5 3294/4885KCNH2 3159/4885 |
| US-20210205305-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | TSHR 1218/4885KCNA5 3294/4885KCNH2 3159/4885 |
| US-10350208-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | TSHR 1218/4885KCNA5 3294/4885KCNH2 3159/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | TSHR 1218/4885KCNA5 3294/4885KCNH2 3159/4885 |
| US-20190282575-A1 | SPIROCYCLIC COMPOUNDS AS TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, HTR1A | TSHR 1218/4885KCNA5 3294/4885KCNH2 3159/4885 |
| US-20090270421-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, CNR2 | TSHR 1415/4885KCNA5 504/4885KCNH2 107/4885 |
| US-20110183947-A1 | ALPHA-KETO HETEROCYCLES AS FAAH INHIBITORS | FAAH, FAAH2, FADS1 | TSHR 3378/4885KCNA5 458/4885KCNH2 194/4885 |
| US-20230339882-A1 | SHP2 INHIBITOR AND COMPOSITION AND APPLICATION THEREOF | PTPRF, PTPRCAP, PTPRJ | TSHR 3019/4885KCNA5 4744/4885KCNH2 4821/4885 |
| US-20170144971-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | TSHR 4432/4885KCNA5 4353/4885KCNH2 4697/4885 |
| US-10946018-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | TSHR 1218/4885KCNA5 3294/4885KCNH2 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.